The Remember Me feature is an automatic login process which creates a cookie on the hard drive of your computer containing a unique identifier which ASCO.org will utilize to remember you by, thereby avoiding the need to enter username and password upon subsequent visits to ASCO.org. DO NOT select this option if you share this computer with others since transactional, personal, or member only information will be accessible by other users.
To activate the Remember Me option, click the empty check box when signing in to the site. The Remember Me functionality is deactivated at the logout.
For additional information please review our Privacy Policy.
STUDIES ADVANCE TREATMENT AND UNDERSTANDING OF LUNG CANCER
FOR IMMEDIATE RELEASE: May 30, 2009
CONTACT: Annual Meeting News Room Phone
407-685-5412
Orlando, Fla.— The findings from several large studies on lung cancer were released today at a press briefing at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO).
"Lung cancer is one of the most challenging cancers to treat, but the studies presented today highlight promising new targeted therapies and milder treatment regimens that improve survival," said Bruce E. Johnson, MD, Director of the Dana-Farber Harvard Medical Center Lung Cancer Program and moderator of the press briefing. "Researchers also report that hormone therapy among menopausal women with lung cancer is associated with a higher risk of death. These findings add to growing concerns about the safety of hormone therapy."
Studies highlighted in the press briefing include:
Pemetrexed extends survival as maintenance therapy: A phase III study reports that maintenance therapy with pemetrexed (Alimta) improves overall survival in nonsquamous forms of advanced non-small cell lung cancer (NSCLC).
Maintenance therapy with two targeted therapies is superior to one alone: A phase III trial finds that adding erlotinib (Tarceva) to bevacizumab-based (Avastin) maintenance therapy in patients with advanced NSCLC delays cancer progression more than maintenance treatment with bevacizumab alone.
Menopausal hormone therapy with estrogen and progestin linked to increased risk of death in women with lung cancer: A secondary analysis from the Women’s Health Initiative reports that use of hormone therapy with estrogen plus progestin increases the risk of dying from NSCLC for women with the disease.
Novel therapy that targets two receptors benefits patients with advanced lung cancer: A phase III trial demonstrates that vandetanib (Zactima), a novel drug that targets two key receptors associated with lung cancer growth, improves progression-free survival in patients with advanced NSCLC.
For consumer-oriented information on these studies and more than 120 cancer types, please refer your readers to ASCO’s patient website, www.Cancer.Net.
